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Abstract 
Previous studies have demonstrated that 17P-estradiol can modify apolipoprotein 
E (apoE) expression. I found that apoE protein varied as a function of the estrous cycle 
and 17P-estradiol (E2) in a region specific manner in the mouse brain. I also found that 
apoE concentration was lowest on estrus in the hippocampus, cingulate cortex and frontal 
cortex; apoE concentration was highest on estrus in the olfactory bulb and cerebellum. 
No changes in apoE were found in the striatum throughout the estrous cycle. Exogenous 
E2 significantly raised tissue levels in the olfactory bulb and cerebellum, but did not 
increase apoE in cortical samples nor in the striatum. E2 elevates levels of apoE in a 
region- and cycle day-specific manner that may be related to the estrogen receptor 
subtype in that area. 
Introduction 
Apolipoprotein E (apoE) is a 299 amino acid component of lipoproteins with a molecular 
weight of 34-kDa. ApoE plays a vital role in the regulation of lipoprotein metabolism and in the 
control of lipid transport and lipid redistribution among target tissues and cells (Mahley, 1988, 
Weisgraber, 1994). Lipid transport and redistribution is regulated by apoE via interaction with 
lipoprotein receptors (Mahley, 1988). Cellular uptake and degradation of the lipoproteins is 
initiated by receptor-lipoprotein binding. The lipid becomes available for utilization in the 
regulation of intracellular cholesterol metabolism. ApoE, therefore, serves as a ligand for the 
receptor-mediated clearance of lipoproteins from the plasma (Rall et al., 1982). 
The ApoE Gene: 
An 1163-nucleotide mRNA encodes apoE. The apoE gene is 3597 nucleotides in length 
and contains four exons (Mahley, 1988). In humans, apoE is a polymorphic protein, existing as 
three common isoforms (apoE2, apoE3, and apoE). These are products of the three alleles 
(designated £2, £3, and £4 respectively) located at a single gene locus on the long proximal arm 
of chromosome 19 (Holtzman, 2000). The molecular basis of this polymorphism of the apoE 
gene results from cysteine-arginine interchanges at two positions in the apoE protein 
(Weisgraber, 1994). These single amino acid substitutions are found at residues 112 and 158 
(Rall, 1982). The most common isoform, apoE3, contains cysteine at residue 112 and arginine at 
position 158. ApoE2 has cysteine at both positions and apoE4 contains arginine at both positions 
(Weisgraber, 1994). 
ApoE Synthesis and Function: 
The largest quantity of apoE is synthesized in the liver followed by the brain and many 
other organs (Boyles, 1985). In these organs, a wide variety of cell types are capable of 
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producing apoE, which includes oligodendrocytes (Stoll., 1989), astrocytes (Pitas, 1987), and 
macrophages (Mahley, 1988). In addition to its previously mentioned function of lipid 
metabolism, apoE has also been implicated in a wide variety of other physiological processes 
throughout the body. ApoE may have a structural role in a number of lipoprotein particles as 
well as regulating their metabolism (Wisniewski and Frangione, 1992). ApoE is also thought to 
function in immunoregulation (Cuthbert and Lipsky, 1984), nerve growth, nerve repair and 
regeneration in both the central nervous system (CNS) and the peripheral nervous system (PNS), 
(Ignatius, 1986; Ignatius, 1987; Snipes, 1986; Boyles, 1989; Handelmann, 1992), modulation of 
intracellular cholesterol utilization (Reyland, 1991 ), steroidogenesis in adrenal cells (Rey land 
and Williams, 1991 ), and as an activator or modulator of hepatic lipase (Ehnholm, 1984; Landis 
et al., 1987; Thurin et al., 1991, 1992). ApoE is thought to participate in the regeneration of 
peripheral nerves after injury (Boyles et al., 1989), and in the mobilization and redistribution of 
lipids during normal development of the nervous system (Pitas et al., 1987). 
ApoE in the Nervous System: 
The exact function of apoE in the nervous system is poorly understood. Injury in either 
the CNS or PNS results in an increase in apoE levels (Ignatius et al., 1986). Following 
peripheral nerve injury in rats, the synthesis of apoE increases by 250- to 350-fold within three 
weeks. (Snipes et al., 1986; Boyles et al., 1989). It has also been reported that macrophages 
synthesize and release apoE following peripheral nerve lesion, which accumulates, to 5% of total 
extracellular protein (Skene and Shooter, 1983). Studies suggest that the purpose of this 
accumulation of apoE is to scavenge cholesterol from the degenerating myelin and recycle it to 
the growth cones of sprouting axons for membrane biosynthesis (Mahley, 1988; Goodrum et al., 
1995; Poirier et al., 1993). 
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Based on these observations, it has been proposed that apoE is involved in 
neurodegenerative processes by isoform-specific effects on cytoskeletal stability and neurite 
outgrowth (Mahley et al., 1995; Weisgraber and Mahley, 1996). In vitro studies with dorsal root 
ganglion neurons have shown that addition of apoE3 to a culture stimulated neurite outgrowth 
whereas apoE4 decreased neurite extension (Nathan et al., 1994). These data imply that apoE is 
important for peripheral nerve regeneration (Mahley, 1988). The data from apoE knockout 
(apoE KO) mice, however, does not support this hypothesis. Regenerating nerves in both control 
mice and apoE KO mice were morphologically identical at two and four weeks following sciatic 
nerve crush (Popko et al., 1993; Goodrum, 1995). This suggests that other apolipoproteins in the 
PNS may substitute for apoE when it is absent. Hence, the specific role of apoE and its 
importance in the PNS remains unclear. 
ApoE is the principle apolipoprotein in the brain and cerebrospinal fluid (CSF). However 
the precise function and mechanism of action of apoE is even less clear in the central nervous 
system. The majority of apoE in the CNS is synthesized and secreted primarily by glial cells, 
followed by microglia (Pitas et al., 1987; Pitas et al., 1987; Borghini et al., 1995; Boyles et al., 
1985; Naikai et al., 1996). ApoE is the only apolipoprotein in the CNS that is able to interact 
with lipoprotein receptors (Pitas et al., 1987; Borghini et al., 1995). Cells within the brain 
express four receptors for apoE-containing lipoproteins: the low-density lipoprotein (LDL) 
receptor, the LDL receptor-related protein (LRP), the very low density lipoprotein (VLDL) 
receptor, and the glycoprotein (gp) 330. The LDL receptor and the LRP are expressed by 
neurons (Pitas et al., 1987; Boyles et al., 1985). It has been shown that the VLDL receptor in the 
CNS is expressed in some human neurons, whereas gp330 is expressed by brain ependymal cells 
(Willnow et al., 1992; Sakai et al., 1994; Kim et al., 1996; Kounnas et al., 1994). It has been 
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reported that human apoE-containing lipoproteins bind to fibroblast LDL receptors and that the 
LDL receptor and the LRP mediate the binding and internalization of apoE-containing 
lipoproteins in cultured neurons (Bellosta et al., 1995). These studies provide evidence that the 
apoE and apoE-containing lipoproteins are present within the brain where they can interact with 
neurons and that lipoprotein transport by apoE is important for normal functioning of adult 
neurons. 
Increased apoE immunoreactivity is present in the brains of patients with such 
neurological disorders as Down's syndrome, Creutzfeld-Jacob disease, and Alzheimer's disease 
(AD) (Namba et al., 1991). It has been demonstrated that expression of apoE increases 
following optic nerve injury, but absolute levels of apoE do not increase (Ignatius et al., 1986). 
ApoE mRNA is increased in the brains of AD patients (Diedrich et al., 1991) and in response to 
injury in both the CNS (Boyles et al., 1989) and PNS (Snipes et al., 1986). 
It has been shown that addition of apoE4 to a culture inhibits neurite extension, whereas 
apoE3 stimulates neurite outgrowth in transformed murine neuroblastoma (Neuro-2a) cells 
(Bellosta et al., 1995). Recent studies show apoE KO mice display disruption of the dendritic 
cytoskeleton and significant synaptic loss with age they also show a reduced recovery following 
perforant pathway lesioning (Masliah et al., 1995; Masliah et al., 1996; Masliah et al., 1997). 
Synaptophysin (a marker for presynaptic terminals) and microtubule-associated protein (MAP-2, 
a dendritic marker) levels in the hippocampus and neocortex of apoE KO mice were shown to 
decrease as compared to age-matched control mice. However, other studies have not observed 
any significant morphological deficits in apoE KO mice (Anderson et al., 1998). The reasons 
underlying these inconsistencies are not clear, but differences in the strain and age of both the 
apoE KO and the control mice used may have contributed to the inconsistent results observed. 
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In contrast to the morphological studies, behavioral studies have consistently shown that 
apoE KO animals exhibit spatial learning deficits (Masliah et al., 1996; Gordon et al., 1995; 
Gordon et al., 1996). Infusion of recombinant apoE into the lateral ventricles of apoE KO mice 
reversed behavioral and morphological anomalies (Masliah et al., 1996). Other studies involving 
apoE KO mice have suggested that apoE is involved in protecting the brain against acute injury 
(Chen et al., 1997). These results provide convincing evidence that apoE plays a critical role in 
preservation, neuroprotection, and plasticity within the CNS. 
Alzheimer's Disease 
By studying apoE within the CNS some questions have been answered about 
neurodegenerative disorders, especially Alzheimer's disease (AD). The apoE genotype has been 
shown to be a major risk factor for AD. ApoE immunoreactivity is associated with the 
characteristic pathological structures present in the brains of AD patients, neurofibrillary tangles 
and neuritic plaques (Namba et al., 1991; Wisniewski and Frangione, 1992; Schmechel et al., 
1993; Strittmatter et al., 1993). Neurofibrillary tangles are intracellular and contain structures 
known as paired helical filaments (Goedert et al., 1992). The neuritic plaques are, for the most 
part, extracellular and constitute classical amyloid deposits and often a neuritic component. The 
major protein present in these plaques is the amyloid beta peptide (Ab), which is formed by 
cleavage of the amyloid precursor protein (APP) (Haass and Selkoe, 1993). Studies have shown 
that apoE is associated with Ab deposits in neuritic plaques and in the angiopathy of cerebral 
vessels (Strittmatter et al., 1993). The role of these plaques and tangles in the progression or 
onset of AD is not yet clear. 
There are two types of AD: familial Alzheimer's disease (FAD), and late-onset sporadic. 
FAD represents approximately 5% of patients and usually occurs before the age of 65, whereas 
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late-onset AD accounts for a majority of AD cases and occurs after the age of 60 (Digivanna, 
2000). Recent studies have indicated a relationship between the apoE4 allele and late-onset AD 
(Strittmatter, 1993). It has been demonstrated that the risk of early-onset AD and disease 
progression increase is related to the number of apoE4 alleles in a dose-dependent fashion (Tsai 
et al., 1994; Corder et al., 1993 ). The frequency of the apoE4 allele has been greatly over-
represented in late-onset AD patients (representing 52% of the subjects) versus controls (16%), 
and the risk of AD in individuals homozygous for the apoE4 allele is over five times that of 
homozygous apoE3 individuals (Corder et al., 1993). 
Another recent study suggests that the apoE4 allele may also be involved with age of 
onset in Parkinson's disease. This evidence strongly suggests that there is a definite correlation 
between apoE polymorphism and the development of neurodegenerative disorder (Nisar, 1999). 
The mechanism behind the pathogenesis of these disorders and the exact effects of apoE on CNS 
neurons remain unclear. One possible mechanism of apoE in AD may involve neuronal 
plasticity, based on previous studies, which suggest that apoE may play a crucial role in nerve 
regeneration. 
AD and Estrogen: 
In addition to apoE genotype, it seems that estrogen plays an important protective role in 
the development of AD. Estrogen is a hormone dominant in the female reproductive system. 
Estrogen can improve blood circulation in the brain as well as stimulate nerve cell growth. It has 
also been shown to increase levels of acetylcholine, and it impedes the deposition of ~-amyloid 
(Inestrosa et al., 1998 ). The risk of AD and related dementia for women who used estrogen 
replacement therapy (ER T) was reduced by about one third below that of women who had never 
used ERT (Paganini-Hill and Henderson, 1996). Recent studies have suggested that estrogen's 
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protective effects are through its action as a trophic factor for cholinergic neurons, a modulator 
for the expression of apoE in the brain, or an antioxidant compound decreasing the neuronal 
damage caused by oxidative stress (Inestrosa et al., 1998). 
As seen earlier it has been demonstrated that ERT increases cerebral and cerebellar blood 
flows in postmenopausal women (Ohkura et al., 1995). Cerebral blood flow values are shown to 
be higher in females than in males until the age of 50 (Davis et al., 1983) or 60 (Shaw et al., 
1984 ). Furthermore, ERT improves cognitive functions and increases regional cerebral blood 
flow in female patients with dementia of the Alzheimer type (Ohkura et al., 1994). 
Estrogen, glial cells and ApoE 
It has been clearly shown that estrogen replacement therapy (ER T) reduces the risk of 
AD and also delays the age of clinical onset (Waring et al., 1999; Paganini-Hill, 1994). It has 
also been found that estrogen replacement in experimental animals promotes recovery from 
neurological damage (Stone et al., 1998; Stone et al., 1997; Toung et al., 1998), and that estrogen 
administration increases apoE and glial markers. The exact mechanism by which estrogen 
facilitates nerve repair is still unknown. As shown above both astrocytes and microglia produce 
apoE. Estrogen appears to regulate apoE gene expression in an organ specific manner 
(Srivastava et al., 1996). Studies have shown that estrogens effects on glia represented an 
interaction between neurons and glial cells (Stone et al., 1998). 
There is a great deal of emerging evidence that ERT both reduces AD and slows 
cognitive decline in women (Stone et al., 1998). Parallel studies in mice, evaluating the effects 
of long-term estrogen elevation, found only transient changes in the synaptic density of olfactory 
neurons (Nathan, personal communication). These results suggest that estrogen's effects on the 
CNS, in neurologically intact animals, are only transitory. 
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Estrogen Receptors 
Estrogen receptors have been reported in astroglia, sheathing glia, and microglia 
(Azcoitia et al., 1999; Mor et al., 1999). Until recently it was thought that the actions of estrogen 
were mediated by a single nuclear estrogen receptor. Studies have found that there are two types 
of estrogen receptors, the classic ER-a., and the novel ER-~ (Shughrue et al, 1997). Neurons of 
the olfactory bulb, cerebellum, and areas of the hypothalamus show exclusively ER~. Both 
receptor types are found throughout the rostral-caudal extent of the brain. The region specific 
expression of ER-a. and ER-~ is proving to be important in determining the physiological 
responses of neuronal populations to estrogen action (Shughrue et al, 1997). 
Aim of the Study 
The objectives of this study were to measure brain region specific concentrations 
of apoE protein during the estrous cycle in the mouse and to determine if exogenous E2 
could alter levels of apoE protein. My hypothesis is that E2 will modulate apoE levels in 
a region specific manner. The rationale behind this hypothesis is the differential 
localization ofERa., and ER~. 
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Materials and Methods 
Mice I Treatment groups 
For this study I used control female mice (Jax control) that were 2-3 months in 
age. For the estrous cycle experiment the estrus phase was the treatment group. For the 
exogenous estradiol experiment the treatment groups included; ovariectomized /Estrogen 
pellet /Saline irrigated and ovariectomized /Placebo pellet /Saline irrigated. Males were 
used as a comparison in this study. 
Vaginal smears 
Normal, female mice approximately 2-3 months old at the start of the study were 
evaluated by vaginal smears for at least three weeks to assure normal estrous cycles. The 
mice were smeared with IX PBS using a glass Pasteur pipette. Examination of the. 
smears using a phase contrast microscope led to the identification of cell types. 
Nucleated epithelial cells signify proestrus, comified epithelial cells signify estrus and 
leukocytes are found in diestrus. 
Surgery 
Animals were either ovariectomized (OVX) or sham operated, depending on the 
treatment group. All animals were anesthetized with an intraperitoneal injection of 
sodium pentobarbital (80 mg/kg). The incision site was shaved and an aseptic bilateral 
dorsal incision made just under the rib cage. The fallopian tube was clamped just below 
the ovary and the ovary was then completely removed. The muscle layer was sewn with 
silk ligatures and the skin was closed with auto clips. The same procedure was followed 
on the opposite side. In the sham operation the same procedure was followed except the 
ovary was not removed. 
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Sacrifice 
Control female mice were sacrificed on the following days of the estrus cycle, 
proestrus, estrus, and diestrus. Mice were anesthetized by an intraperitoneal injection of 
sodium pentobarbital (80mg/kg). After the animals were deeply anesthetized, a needle 
was inserted transcardially and the animals were thoroughly perfused with phosphate 
buffered saline (pH 7.4). The brain was removed from the skull case and the following 
areas were dissected using visual guidance: 1) olfactory bulb; 2) frontal cortex dorsal to 
the rhinal fissure; 3) cingulated cortex; 4) hippocampus; 5) striatum; and 6) cerebellar 
cortex. In addition three males were prepared similar to the females. 
Tissue Preparation 
The samples were homogenized in ice cold TMN buffer (25 mM Tris-HCl [pH 
7.6] 3 mM MgCh, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride) (Xu et al., 
1996). The homogenate was lysed by adding 1 % Triton X-100, 0.5% deoxycholate, and 
0.2% SDS on ice for 5 min (Xu et al., 1998). The homogenate was then centrifuged for 2 
min in a microcentrifuge (g = 13,000) (Xu et al., 1998). The supernatant was saved for 
protein assay and western immunoblot analysis. 
Protein Assay 
Protein assay was performed by BCA protein assay method as described by the 
manufacturer (Pierce). Briefly, 1 µl of homogenized sample was diluted to 99 µl with 
double distilled water, and 30 µl of diluted samples (in triplicates) were assayed. 
SDS - Polyacrylamide Gel Electrophoresis 
Proteins in the olfactory bulb were resolved by SDS-PAGE as previously 
described (Bellosta et al., 1995). Briefly, 20 µg of sample protein was mixed with an 
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equal volume of 2X Lammeli sample buffer (6.25 ml 4X Tris/SDS [pH 6.8], 5 ml 
glycerol, lg SDS, 0.5 ml 2-mercaptoethanol, bromophenol, 13.25 ml dH20). Samples 
were boiled for 5 min and then centrifuged at 14,000 g for 5 min. The gel cassettes were 
inserted into the buffer tank of an EC 120 Mini gel vertical system (E-C Apparatus 
Corporation, St. Petersburg, FL) containing IX running buffer, pH 8.3 [250 ml of 5X 
running buffer (15 g Tris-base, 72 g glycine, 5 g SDS, 750 ml dH20]. 
The samples and 5 µl of kaleidoscope prestained standards (161-0324, Bio-Rad 
Laboratories, Hercules, CA) were electrophoresed through a pre-cast 4-20% gradient gel 
(Fisher, FB3435). Samples were electrophoresed at 80 volts until separation began, and 
then at 140 volts until the dye front reached the bottom of the gel. 
Protein Transfer 
Following electrophoresis, the gel was placed in transfer buffer (3.03 g Tris-base, 
14.4 g glycine, 200 ml methanol, 800 ml dH20) on a shaker. The transfer membrane 
(Immobilon-P IPVHOOOlO, Millipore, Bedford, MA) was soaked in methanol for 5 sec 
and then washed in dH20 for 5 min. The gel was placed on presoaked filter paper in the 
holder and the transfer membrane was placed on top of the gel. Using a trans-blot transfer 
cell (170-3930, Bio-Rad), proteins from the gel were transferred onto the membrane by 
passing 100 volts for an hour. 
Western Blotting 
Apolipoprotein E 
ApoE was quantified as previously described (Xu et al., 1996). Briefly, the blots 
were incubated in polyclonal goat antiserum against human apoE (178479, Calbiochem, 
San Diego, CA) (1 :5,000 dilution in T-TBS [pH 7.6] O. lM Tris, O. l 5M NaCl, 0.1 % 
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Tween-20) for 30 min on a shaker at room temperature. The membrane was then washed 
5 times (10 min each) in T-TBS. The blot was then incubated in the secondary antibody 
solution (rabbit anti-goat IgG-HRP [AP106P, Chemicon, Temecula, CA] 1:10,000 
dilution) for 30 min on a shaker at room temperature. Blots were washed with T-TBS 6 
times (10 min each) (Xu et al., 1996). Immunoreactive bands were then visualized with 
SuperSignal West Pico Chemiluminescent substrate (34080, Pierce, Rockford, IL) and 
then exposed to BioMax film (Kodak). 
Ouantitation/Data Analysis 
All experiments were repeated at least three times to assure reproducibility of the 
results. Bands were quantified by densitometry (Scion Image). As an internal control, the 
blots also contained an olfactory bulb extract from unlesioned control female animals. 
Statistical analysis of the immunoblot data was by a repeated measures analysis of 
variance (Systat 10) with region as the repeated measure and the part of the estrus cycle 
as the independent measure. When a statistically significant interaction between region 
and condition was found, we performed a one-way analyses of variance to further specify 
the character of the significant differences found in the initial analysis. 
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Results: 
In this study, female mice 2-3 months old were evaluated by vaginal smears for at 
least three weeks to assure normal estrous cycles. Groups of three mice were sacrificed 
on diestrus, proestrus, and estrus. The brain was removed' from the skull case and the 
following areas were dissected using visual guidance: 1) olfactory bulb; 2) frontal cortex 
dorsal to the rhinal fissure; 3) cingulated cortex; 4) hippocampus; 5) striatum; and 6) 
cerebellar cortex. In addition three males were prepared similar to the females. 
Statistical significance was found for estrus (F=l 7:01, df=2,6; p<0.003), region (F=8.57; 
df=5,30; p<0.001) and for the interaction between cycle and regions (F=9.60;df=10,30; 
p<0.001). The simple main effects of estrus and regions showed that total apoE regional 
concentrations of apoE were higher on proestrus and diestrus than on estrus. Olfactory 
bulb showed the highest concentration and cerebellum the lowest irrespective of cycle 
stage. However the significant interaction of estrus by region limits any interpretation of 
simple main effects. 
Post-hoc analysis with one-way analysis of variance found that the hippocampus 
(F=13.57, df=2,6; p<0.006), cingulate (F=14.83, df=2,6; p<0.005) and frontal (F=25.95, 
df=2,6; p<0.001) showed minimum apoE expression on estrus and roughly comparable 
levels during proestrus and diestrus (figures 1,2,&3). Conversely, in both olfactory bulb 
(F=61.00, df=2,6; p<0.001) and cerebellum (F=39.00 df=2,6; p<0.001) peak levels of 
apoE occurred during estrus (Figures 4&5). The caudate-putamen complex showed no 
differences as a function of estrus cycle (F=0.139, df=2,6; p<0.873)(Figure 6). Analysis 
of the regional data from males (n=3) did not find statistical significance among brain 
regions (F=l.659; df=5,10; p<0.232). However, the same regional pattern was obtained 
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as in females. The olfactory bulb had the highest concentration of apoE, the cerebellum 
lowest and cortical areas were intermediate. The small sample size for males (n=3) 
probably resulted in non-significance. The apparent difference between males and 
females in total apoE could not be analyzed as immunoblots were performed a disparate 
time. 
Exogenous E2 increased apoE in OVX mice. We found a significant E2 effect 
(F=28.85; df=l,4; p<0.006), a significant region effect (F=39.213; df=5,20; p<0.001) and 
a significant region by E2 interaction (F=3.789; df=5,20; p<0.014) in the initial analysis 
of variance. E2 replacement resulted in a 68% increase in overall apoE. OB had the 
highest levels of apoE. In contrast to the previous analysis, the cingulate showed the 
lowest levels of apoE pooled over the two E2 conditions. However, the presence of a 
significant region by E2 interaction limited further conclusions. Post-hoc analysis of the 
interaction, with a one-way ANOV A, found a 74% increase of apoE with E2 in olfactory 
bulb (F=23.90; df=l,4; p<0.008)(Figure 7) and a 110% increase in cerebellum (F=48.40; 
df=l,4; p<0.002)(figure 8). E2 effects in hippocampus (F=4.70; df=l,4; p<0.096), frontal 
(F=l .78; df=l,4; p<0.253) and cingulate (F=l.58; df=l,4; p<0.277) did not reach 
statistical significance(Figures 9,10,11). Caudate showed no effect ofE2 (F=0.295; 
df=l,4; p<0.616)(figure 12). 
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Figure 1: ApoE concentrations (mean± SE) in hippocampus during the estrous cycle. 
Significant differences are seen during estrus when compared to the other phases. Males, 
which show levels of apoE similar to proestrus are included for comparison. 
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Figure 2: ApoE concentrations (mean± SE) in the cingulate and the estrous cycle. 
Proestrus and diestrus have approximately equal levels of apoE while estrus has 
significantly less. Males are included for comparison and have apoE levels similar to 
proestrus and diestrus. 
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Figure 3: ApoE concentrations (mean± SE) in the frontal lobe and the estrous cycle. 
Levels of apoE are highest in proestrus and diestrus followed by estrus. Males are 
included for comparison and have apoE levels similar to diestrus. 
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Figure 4: ApoE levels (mean± SE) in the olfactory bulb and estrous cycle. Estrus had 
the highest levels of apoE followed by diestrus and proestrus. Males are included for 
comparison and have apoE concentrations comparable to estrus. 
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Figure 5: ApoE levels (mean ± SE) in the cerebellum during the estrous cycle. ApoE 
levels are highest in estrus followed by proestrus and diestrus. Males are included for 
comparison and have apoE levels similar to estrus. 
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Figure 6: ApoE levels (mean± SE) in the caudate putamen (striatum) during the estrous 
cycle. ApoE levels are approximately the same for all three stages. Males are included 
for comparison. 
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Figure 7: 17P-estradiol effects on apoE levels (mean± SE) in the olfactory bulb. When 
compared to placebo, 17P-estradiol significantly increased apoE concentrations in the 
olfactory bulb. 
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Figure 8: 17~-estradiol effects on apoE levels (mean± SE) in the cerebellum. When 
compared to placebo, 17~-estradiol significantly increased apoE concentrations in the 
cerebellum. 
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Figure 9: 17~-estradiol effects on apoE levels (mean± SE) in the hippocampus. No 
significant effects were found between placebo and 17~-estradiol treated groups. 
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Figure 10: 17~-estradiol effects on apoE levels (mean± SE) in the frontal lobe. No 
significant effects of were found between placebo and 17~-estradiol treated groups. 
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Figure 11: 17P-estradiol effects on apoE levels (mean± SE) in the cingulate. No 
significant effects were found between placebo and 17P-estradiol treatment groups. 
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Figure 12: 17~-estradiol effects on apoE levels (mean± SE) in the caudate putamen 
(striatum). No significant effects were found between placebo and 17~-estradiol treated 
groups. 
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Discussion: 
Previous studies on the effects of lesioning and estrogen on apoE levels in the 
olfactory bulb revealed that estrogen is required for upregulation of apoE levels. 
Estrogen also influences synaptic sprouting in the dentate gyrus in response to injury via 
an apoE-depend~nt mechanism (Stone, 1998). Regions of the hippocampus and 
hypothalamus both showed synaptic remodeling during the estrous cycle and, apoE 
mRNA levels fluctuated according to the stages. In proestrus when E2 levels are 
elevated apoE mRNA levels are at a maximum. However, 24 hours later in estrus apoE 
mRNA levels are 30% less in the hypothalamus and CAI region of the hippocampus 
(Stone, 97). Changes in synaptic density in the CAI region of the hippocampus during 
the estrus cycle showed the same pattern as apoE mRNA levels with the highest synaptic 
density corresponding to proestrus, which is the peak of estrogen, (Woolley, 1992). 
Differential distribution and regulation of estrogen receptors throughout the brain 
(Osterlund, 1998) is presumed to be the reason for differences in the effects of estrogen 
on ApoE. By using the estrus cycle and ovariectomies plus pellet placement as my 
models I was able to examine the effects of estrogen on apoE levels throughout various 
brain regions. Male mice were used as a baseline in this study. 
Statistically significant differences were found among brain regions for the 
concentration of apoE in the female mice. Evaluation of the male mice paralleled these 
data although these data did not reach significance. OB showed the highest concentration 
of apoE and cerebellum showed the lowest; cortical areas and hippocampus results fell 
between. The data show substantial regional and temporal variation (3-10 fold) during 
the estrous cycle. General statements about apoE protein concentration in female mice 
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require careful consideration of both of these factors in interpretation of endocrine effects 
on brain apoE. 
Striatal concentrations of apoE were not affected by either estrous phases or E2 
replacement. ER mRNA has not been reported in the rat striatum (Shrugrue et al, 1999, 
2000, 2001 ). Estrous cycle neurotransmitter variation in the striatum may represent ER 
present in the substantia nigra, the source of striatal dopamine (Jori et al, 1976, Kritzer, 
1997). 
Regional variation of ER subtypes may underlay regional variation in apoE expression 
during the estrous cycle (Shrugrue et al, 1999, 2000, 2001). These studies reported 
neocortical areas and hippocampus expressed message for both ERa. and p in rats. The 
olfactory bulb and cerebellum only expressed the P subtype of the ER. The striatum 
expressed neither. I suggest that E2 affects cortical apoE by the ERa.. Activation by ERa 
could account for increasing concentration of apoE in diestrus and proestrus when E2 
levels were increasing. Increased apoE could also be through a non-genomic mechanism 
as has been reported for some actions of E2 (Toran-Allerand et al, 1999; McEwen et al, 
2001 ). In the olfactory bulb and cerebellum, which do not express the ERa in the rat, E2 
stimulation of apoE is by the ERP. Elevation may require prolonged exposure to a higher 
threshold of E2 or an intervening step of glial activation (McEwen, 2001), given that 
there is an estrogen response element in the GF AP (glial fibrillary acidic protein) 
promoter region (Stone, 1998). In this context, it should be noted that my evalu1:1.tion of 
the promoter sequence of the mouse apoE gene revealed a region with significant 
similarity to the estrogen response element at 54 7 bases upstream from the transcriptional 
initiation site. Glial activation and this promoter may interact for apoE production. 
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The OVX-E2 replacement experiments generally paralleled the estrous cycle pattern 
of apoE expression and lend support to our speculation about the possible receptor 
function. The striatum showed no evidence of apoE changes with estrous cycle and was 
unresponsive to E2 replacement or deprivation. A significant effect was found in the 
areas reported to express only the p receptor (olfactory bulb and cerebellum). Significant 
effects were not found in the brain regions that express message for both a and p 
receptors (cortex and hippocampus). This observation is in contrast to a previous paper 
(Levin-Allerhand, 2001) that found an effect in cortex and hippocampus and attributed 
this change to the ERP. This study used a much higher dosage of E2 (Levin-Allerhand, 
2001). The pellets we used maintain circulating levels of E2 between 150-200 pg/ml for 
about eight weeks and literature values for proestrus levels vary between 40-1 OOpg/ml 
(Rozosky, 2002). Sampling five days after E2 replacement/deprivation puts our sampling 
period close to maximal apoE elevation during normal estrous cycling in the olfactory 
bulb and cerebellum (i.e., estrus). Failure to find an E2 effect in areas expressing both 
ERa and p may be an artifact of timing. Sampling at 5 days after deprivation or 
replacement could mask an E2 effect modulated via ERa because the peak activation of 
apoE may have been passed. Pharmacological doses of E2 may be able to override 
homeostatic mechanisms. 
Understanding the relationship between estrogen and apoE is clinically relevant. 
Hormone replacement therapy (HR T) decreases the risk for developing dementia 
(Brenner, 1994; Tang, 1996; Paganini-Hill, 1994), is associated with a later onset and less 
malignant course of Parkinson's disease (Kuopio, 1999; Saunder-Pullman, 1999), and 
decreases the risk or improves prognosis following stroke (Paganini-Hill, 1995). 
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Increased synaptic sprouting in response to estrogen requires apoE (Stone, 1998). We 
speculated previously that apoE may be involved in repair and recycling of membrane 
materials (Nathan, 2001). Because apoE is intimately involved in utilization of 
cholesterol and membrane integrity in the CNS, HRT could function by changing levels 
of apoE which, in tum, could enhance cholesterol utilization. Protective effects of HRT 
could be acting through an apoE-based mechanism. 
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